Blueprint, AstraZeneca ink deal to evaluate combination of lung cancer therapies in ongoing trials
Blueprint Medicines (NASDAQ:BPMC) on Friday announced a clinical trial supply agreement with AstraZeneca (AZN) under which it will evaluate its investigational agents BLU-945 and BLU-701 in combination with osimertinib in its ongoing SYMPHONY and HARMONY trials, respectively.
Blueprint also announced data from the phase 1/2 SYMPHONY trial of BLU-945 for the treatment of advanced EGFR-mutant non-small cell lung cancer.

Data reported at American Association for Cancer Research annual meeting.
The trial results showed early evidence of safety and clinical activity consistent with preclinical data, supporting plans to expand development of BLU-945 in combination with multiple agents including AstraZeneca's osimertinib.
The company said it is initiating a SYMPHONY trial cohort to evaluate BLU-945 in combination with osimertinib.